Received Jun 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | RA |
redness at the injection site; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 75-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. Concurrent medical conditions included supraventricular tachycardia (History of SVT - had ablation done to treat). Concomitant products included Multivitamin. On 11-JUN-2025, the patient received Arexvy (right arm). On 11-JUN-2025, less than a day after receiving Arexvy, the patient experienced injection site erythema (Verbatim: redness at the injection site). On 12-JUN-2025, the outcome of the injection site erythema was resolved (duration 1 day). It was unknown if the reporter considered the injection site erythema to be related to Arexvy. It was unknown if the company considered the injection site erythema to be related to Arexvy. Additional Information: GSK Receipt Date: 13-JUN-2025 The reporter was the patient. The patient received Arexvy on Wednesday 11 June 2025 in the right arm. The patient noticed redness at the injection site the day of the vaccination, and it was gone the next day.
Supraventricular tachycardia (History of SVT - had ablation done to treat)
Multivitamin